Versuchen GOLD - Frei

FDA Cites Failure to Report GLP-1 Risks

The Wall Street Journal

March 11, 2026

Novo Nordisk said it is working quickly to respond to the FDA's request.

- BY ELIAS SCHISGALL

Novo Nordisk received a warning from the Food and Drug Administration for failing to report serious suspected side effects in patients who took the company's GLP-1 treatments.

Diese Geschichte stammt aus der March 11, 2026-Ausgabe von The Wall Street Journal.

Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.

Sie sind bereits Abonnent? Anmelden